¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Androgen excess"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® androgen ÇÑ±Û ³²¼ºÈ£¸£¸ó, ¾Èµå·Î°Õ
¼³¸í   
  ³²¼ºÀÇ ÀÌÂ÷ ¼ºÂ¡À» ³ªÅ¸³»°Ô Çϴ ȣ¸£¸ó. Å×½ºÅ佺Å×·Ð(testosterone), ¾Èµå·Î½ºÅ×·Ð(androsterone) µîÀÌ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    1. ³²¼ºÈ£¸£¸ó 2. ¾Èµå·Î°Õ
  • androgen binding protein
    ¾Èµå·Î°Õ°áÇմܹéÁú
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • accommodative excess
    Á¶Àý°ú´Ù
  • base excess
    ¿°±â°úÀ×
  • convergence excess
    ´«¸ðÀ½°ú´Ù
  • divergence excess
    ´«¹ú¸²°ú´Ù, °³»ê°ú´Ù
  • divergence excess exotropia
    ´«¹ú¸²°ú´Ù¿Ü»ç½Ã, °³»ê°ú´Ù¿Ü»ç½Ã
  • excess
    °ú´Ù, °úÀ×
  • excess chlorine
    °úÀ׿°¼Ò
  • excess mortality
    Ãʰú»ç¸Á·ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    1.³²¼ºÈ£¸£¸ó, 2.¾Èµå·Î°Õ
  • total androgen
    ÃѾȵå·Î°Õ
  • excess
    °ú´Ù, °úÀ×
  • antigen excess
    Ç׿ø°úÀ×
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    ¾Èµå·Î°Õ, ³²¼ºÈ£¸£¸ó
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • base excess
    ¿°±â°úÀ×
  • convergence excess
    ´«¸ðÀ½°ú´Ù
  • excess chlorine
    °úÀ׿°¼Ò
  • divergence excess
    ´«¹ú¸²°ú´Ù
  • divergence excess exotropia
    ´«¹ú¸²°ú´Ù¿Ü»ç½Ã
  • excess
    °ú´Ù, °úÀ×
  • excess mortality
    Ãʰú»ç¸Á·ü
  • excess sludge
    °úÀ×Â±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • ABP=> androgen-binding protein
    ¾Èµå·ÎÁ¨°áÇմܹé
  • androgen
    ¾Èµå·Î°Õ
  • androgen
    ³²¼ºÈ£¸£¸ó, ¾Èµå·Î°Õ, ¾Èµå·ÎÁ¨
  • androgen
    ¾Èµå·Î°Õ, ³²¼ºÈ£¸£¸ó(Ñûàõ¡­)
  • androgen
    ³²¼ºÈ£¸£¸ó, ¾Èµå·Î°Õ.
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    ³²¼ºÈ£¸£¸ó, ¾Èµå·Î°Õ, ¾Èµå·ÎÁ¨
  • androgen
    ¾Èµå·Î°Õ, ³²¼ºÈ£¸£¸ó(Ñûàõ¡­)
  • androgen
    ³²¼ºÈ£¸£¸ó, ¾Èµå·Î°Õ.
  • androgen
    ¾Èµå·Î°Õ
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • androgen insensitivity
    ³²¼ºÈ£¸£¸ó ¹«°¨ÀÀ
  • androgen insensitivity syndrome
    ¾Èµå·Î°Õ( ³²¼ºÈ£¸£¸ó) ºÒ°¨¼º ÁõÈıº(ÝÕÊïàõ ñøý¦ÏØ)
  • androgen receptor
    ³²¼ºÈ£¸£¸ó ¼ö¿ëü
  • androgen therapy
    ³²¼ºÈ£¸£¸ó ¿ä¹ý
  • androgen, androgenic steroid
    ³²¼º(È­)È£¸£¸ó, ³²¼ºÈ­½ºÅ×·ÎÀ̵å.
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • androgen-resistance syndrome
    ³²¼ºÈ£¸£¸ó ³»¼º(ÀúÇ×)ÁõÈıº?
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    ¾Èµå·ÎÀü
  • androgen-binding protein
    ¾Èµå·ÎÀü°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • atomic percent excess
    °ú´Ù ¿øÀÚ¹éºÐÀ²(ΦÒýê«í­ÛÝÝÂëÒ)
  • primary alkali excess
    ¿ø¹ß¼º(ê«Û¡àõ) ¾ËÄ®¸®°úÀ×(Φí¥)
  • primary carbon dioxide excess
    ¿ø¹ß¼º ÀÌ»êȭź¼Ò(ê´Û¡àõ ì£ß«ûù÷©áÈ) °úÀ×(Φí¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    ³²¼ºÈ£¸£¸ó, ¾Èµå·Î°Õ
  • excess
    °úÀ×, À׿©
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AIS Androgen Insensitive Syndrome
  = Testicular Feminization Syndrome
AA abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];...
AACSH adrenal androgen corticotropic stimulating hormone
AASH adrenal androgen stimulating hormone; American Association for the Study of Headache
ABP actin-binding protein; ambulatory blood pressure; American Board of Pedodontics; American Board of P...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AME Apparent Mineralocorticoid Excess
BE Base Excess
EWL Excess Weight Loss
EPOC Excess post-exercise oxygen consumption
RAEB RA with an excess of blasts
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • E28.1
    Androgen excess
    ¾Èµå·Î°Õ °ú´Ù
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • androgen
    ³²¼º È£¸£¸ó, ¾Èµå·Î°Õ
    1. ³²¼ºÈ­ ÀÛ¿ëÀ» °¡Áø ¹°Áú. 2. ³²¼º È£¸£¸óÀ» ÅëÅо ºÎ¸£´Â À̸§. °íȯ¿¡¼­ ºÐºñµÇ´Â ³²¼º È£¸£¸óÀ¸·Î´Â testosterone, dihydrotestosterone ¹× androstenedion µîÀÌ ÀÖ´Ù. ÀÌÁß¿¡¼­µµ testosteroneÀÇ ºÐºñ·®ÀÌ °¡Àå ¸¹°í ³²¼º È£¸£¸óÀÇ È¿´Éµµ °¡Àå °­ÇÏ´Ù.
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • androgen insensitivity syndrome
    ¾Èµå·Î°Õ ºÒ°¨¼º ÁõÈıº
  • androgen resistance syndrome
    ³²¼º È£¸£¸ó ³»¼º ÁõÈıº, ³²¼º È£¸£¸ó ÀúÇ× ÁõÈıº
  • antibody excess zone
    Ç×ü °úÀ׿ª
  • antigen excess
    Ç׿ø °úÀ×
    ħ°­ ¹ÝÀÀ µî ÃÖÀûºñ¿¡¼­ ¹ÝÀÀÀÌ Àß °üÂûµÇ´Â °æ¿ì Ç׿øÀÇ ¾çÀÌ Áö³ªÄ¡°Ô ¸¹À¸¸é ¹Ý´ë·Î ¹ÝÀÀÀÌ ¾àÇØÁö°í °üÂûÀÌ °¡´ÉÇÑ ¹ÝÀÀÀÌ »ý±æ ¶§±îÁöÀÇ ½Ã°£ÀÌ ±æ¾îÁø´Ù. ÀÌ¿Í °°ÀÌ Ç׿øÀÌ °úÀ×µÇ¾î ¹ÝÀÀÀÌ °üÂûµÇÁö ¾Ê°Ô µÇ´Â °æ¿ì Ç׿ø °úÀ׿¡ ÀÇÇÑ ¹ÝÀÀÀÇ ¾ïÁ¦Çϰí ÇÑ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â Ç׿ø °úÀ×ÀÎ °æ¿ì¿¡´Â °¡¿ë¼ºÀÌ µÈ´Ù.
  • creatinaemia : excess of creatine in the blood.

    creatine kinase

    Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦
  • excess
    °úÀ×, À׿©
  • excess chlorine
    °úÀ× ¿°¼Ò
  • excess factor
    °úÀ× ÀÎÀÚ
  • excess lactate
    °úÀ× À¯»ê, °úÀ× À¯»ê¿°
  • excess sludge
    °úÀ× ½½·¯Áö
  • excess water
    À׿© ¼öºÐ
  • zone of antigen excess
    Ç׿ø °úÀ×´ë
    ºñ±³Àû °í³óµµÀÇ Ç׿ø´ë·Î¼­ ħ°­¹ÝÀÀ¿¡¼­ °¡¿ë¼º º¹ÇÕü°¡ Çü¼ºµÇ¸ç ¹ÝÀÀÀÌ ¾ïÁ¦µÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
adrenal androgen Any androgenic hormone of adrenocortical origin; e.g., dehydroepiandrosterone (and its sulfate), androstenedione, 11b-hydroxyandrostenedione.
(05 Mar 2000)
adrenal androgen-stimulating hormone A putative pituitary hormone that may be responsible for increased secretion of adrenal androgens at the time of puberty.
(05 Mar 2000)
androgen <endocrinology> General term for any male sex hormone in vertebrates. Androgens may be used in patients with breast cancer to treat recurrence of the disease.
(14 May 1997)
androgen antagonists Compounds which inhibit or antagonise the biosynthesis or actions of androgens.
(12 Dec 1998)
androgen binding protein A protein secreted by testicular Sertoli cells along with inhibin and mullerian inhibiting substance. Androgen binding protein probably maintains a high concentration of androgen in the seminiferous tubules.
(05 Mar 2000)
androgen-binding proteins Carrier proteins produced in the sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. Participate in the transport of androgens; include also synthetic androgens binding proteins.
(12 Dec 1998)
androgen-dependent secretory protease <enzyme> Glycoprotein from dog prostate; hydrolyzes arginine and lysine-containing amide and ester protease substrates
Registry number: EC 3.4.99.-
Synonym: ads-protease
(26 Jun 1999)
androgen resistance syndromes A class of disorders associated with 5a-steroid reductase deficiency, testicular feminization, and related disorders.
Compare: steroid 5a-reductase, Reifenstein's syndrome, infertile male syndrome, testicular feminization syndrome.
(05 Mar 2000)
androgen unit The androgenic activity of 100 ug (0.1 mg) of crystalline androsterone as assayed by the comb growth response in capons.
(05 Mar 2000)
receptors, androgen Proteins, generally found in the cytoplasm, that specifically bind androgens and mediate their cellular actions. The complex of the androgen and receptor migrates to the nucleus where it induces transcription of specific segments of DNA.
(12 Dec 1998)
anaemia, refractory, with excess of blasts Chronic refractory anaemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
(12 Dec 1998)
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
base excess A measure of metabolic alkalosis, usually predicted from the Siggaard-Andersen nomogram; the amount of strong acid that would have to be added per unit volume of whole blood to titrate it to pH 7.4 while at 37°C and at a carbon dioxide pressure of 40 mm Hg.
(05 Mar 2000)
calcium excess Overly high intake of calcium (hypercalcaemia) may cause muscle weakness and constipation, affect the conduction of electrical impulses in the heart (heart block) lead to calcium stones in the urinary tract, impair kidney function (through nephrocalcinosis), and interfere with the absorption of iron predisposing to iron deficiency. According to the National Academy of Sciences, adequate intake of calcium is 1 gram daily for both men and women. The upper limit for calcium intake is 2.5 grams daily.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • androgen
    ¾Èµå·Î°Õ(³²¼º È£¸£¸ó)
  • excess
    °ú´Ù(ÀÇ); ÆøÀ½(½Ä)
  • excess
    °úµµ;°ú´Ù;°úÀ×;Ãʰú;Ãʰú·®;ºÎÀýÁ¦;Áö³ªÄ§;³­Æø;ÆøÀ½Æø½Ä(excess of imports over exports ¼öÀÔ Ãʰú) a
  • excess baggage
    Á¦ÇÑ Ãʰú ¼öÇϹ°
  • excess charge
    ÁÖÂ÷ ½Ã°£ Ãʰú ¿ä±Ý
  • excess fare
    öµµÀÇ °Å¸® Ãʰú ¿ä±Ý;Ãʰú ¿ä±Ý
  • excess luggage
    =EXCESS BAGGAGE
  • excess postage
    ¿ìÇ¥ ºÎÁ· ¿ä±Ý
  • excess reserves
    (ÀºÇà)Ãʰú Áغñ±Ý
  • excess supply
    (°æ)°ø±Þ Ãʰú(°úÀ×)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á